Print

Alnylam Pharmaceuticals (ALNY) Receives Notice of Allowance From United States Patent and Trademark Office (USPTO) for New Patents From the Tuschl II Patent Estate Broadly Covering RNAi Therapeutics  
11/26/2012 11:03:50 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for three patent applications from the company’s exclusively held Tuschl II patent estate. The USPTO has allowed claims in patent applications 12/537,602, 12/683,081 and 12/838,786 which cover compositions, methods, and uses of small interfering RNA (siRNA) that are important for the development and commercialization of RNAi therapeutics. These newly allowed claims are the first to emerge from the U.S. prosecution of the Tuschl II patent series that include composition of matter for siRNA, the molecules that mediate RNAi. The Tuschl II patent family is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Max Planck Innovation GmbH, the licensing agent for the Max Planck Society.
//-->